
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3541308/publications.pdf Version: 2024-02-01



DEDER | SMITH

#	Article	IF	CITATIONS
1	Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains. Science Translational Medicine, 2022, 14, .	12.4	55
2	Influenza virus infection history shapes antibody responses to influenza vaccination. Nature Medicine, 2022, 28, 363-372.	30.7	30
3	Defining the risk of SARS-CoV-2 variants on immune protection. Nature, 2022, 605, 640-652.	27.8	117
4	Beneath the surface: Amino acid variation underlying two decades of dengue virus antigenic dynamics in Bangkok, Thailand. PLoS Pathogens, 2022, 18, e1010500.	4.7	5
5	Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct. Science Immunology, 2022, 7, .	11.9	89
6	Plasticity of the Influenza Virus H5 HA Protein. MBio, 2021, 12, .	4.1	8
7	80 questions for UK biological security. PLoS ONE, 2021, 16, e0241190.	2.5	8
8	Antigenic evolution of dengue viruses over 20 years. Science, 2021, 374, 999-1004.	12.6	34
9	Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains. Science Translational Medicine, 2021, , eabm3302.	12.4	13
10	Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus. PLoS Biology, 2021, 19, e3001384.	5.6	15
11	Diverse variola virus (smallpox) strains were widespread in northern Europe in the Viking Age. Science, 2020, 369, .	12.6	108
12	Characterizing Emerging Canine H3 Influenza Viruses. PLoS Pathogens, 2020, 16, e1008409.	4.7	29
13	Characterizing Emerging Canine H3 Influenza Viruses. , 2020, 16, e1008409.		0
14	Characterizing Emerging Canine H3 Influenza Viruses. , 2020, 16, e1008409.		0
15	Characterizing Emerging Canine H3 Influenza Viruses. , 2020, 16, e1008409.		0
16	Characterizing Emerging Canine H3 Influenza Viruses. , 2020, 16, e1008409.		0
17	Characterizing Emerging Canine H3 Influenza Viruses. , 2020, 16, e1008409.		0
18	Characterizing Emerging Canine H3 Influenza Viruses. , 2020, 16, e1008409.		0

#	Article	IF	CITATIONS
19	The Molecular Basis for Antigenic Drift of Human A/H2N2 Influenza Viruses. Journal of Virology, 2019, 93, .	3.4	22
20	Antigenic Drift of the Influenza A(H1N1)pdm09 Virus Neuraminidase Results in Reduced Effectiveness of A/California/7/2009 (H1N1pdm09)-Specific Antibodies. MBio, 2019, 10, .	4.1	57
21	Genetic and antigenic characterisation of influenza A(H3N2) viruses isolated in Yokohama during the 2016/17 and 2017/18 influenza seasons. Eurosurveillance, 2019, 24, .	7.0	18
22	Epistatic interactions can moderate the antigenic effect of substitutions in haemagglutinin of influenza H3N2 virus. Journal of General Virology, 2019, 100, 773-777.	2.9	13
23	Viridot: An automated virus plaque (immunofocus) counter for the measurement of serological neutralizing responses with application to dengue virus. PLoS Neglected Tropical Diseases, 2018, 12, e0006862.	3.0	93
24	Ancient human parvovirus B19 in Eurasia reveals its long-term association with humans. Proceedings of the United States of America, 2018, 115, 7557-7562.	7.1	64
25	Ancient hepatitis B viruses from the Bronze Age to the Medieval period. Nature, 2018, 557, 418-423.	27.8	155
26	Complete assembly of a dengue virus type 3 genome from a recent genotype III clade by metagenomic sequencing of serum. Wellcome Open Research, 2018, 3, 44.	1.8	4
27	Complete assembly of a dengue virus type 3 genome from a recent genotype III clade by metagenomic sequencing of serum. Wellcome Open Research, 2018, 3, 44.	1.8	6
28	Factors determining human-to-human transmissibility of zoonotic pathogens via contact. Current Opinion in Virology, 2017, 22, 7-12.	5.4	21
29	Characterization of influenza A(H1N1)pdm09 viruses isolated from Nepalese and Indian outbreak patients in early 2015. Influenza and Other Respiratory Viruses, 2017, 11, 399-403.	3.4	11
30	Serial Vaccination and the Antigenic Distance Hypothesis: Effects on Influenza Vaccine Effectiveness During A(H3N2) Epidemics in Canada, 2010–2011 to 2014–2015. Journal of Infectious Diseases, 2017, 215, 1059-1099.	4.0	126
31	Antigenic Relationships among Human Pathogenic Orientia tsutsugamushi Isolates from Thailand. PLoS Neglected Tropical Diseases, 2016, 10, e0004723.	3.0	18
32	Influenza B vaccine lineage selection—An optimized trivalent vaccine. Vaccine, 2016, 34, 1617-1622.	3.8	14
33	The confounded effects of age and exposure history in response to influenza vaccination. Vaccine, 2016, 34, 540-546.	3.8	109
34	Selection of antigenically advanced variants of seasonal influenza viruses. Nature Microbiology, 2016, 1, 16058.	13.3	61
35	Enhancing disease surveillance with novel data streams: challenges and opportunities. EPJ Data Science, 2015, 4, .	2.8	119
36	Global circulation patterns of seasonal influenza viruses vary with antigenic drift. Nature, 2015, 523, 217-220.	27.8	445

#	Article	IF	CITATIONS
37	Identification of Amino Acid Substitutions Supporting Antigenic Change of Influenza A(H1N1)pdm09 Viruses. Journal of Virology, 2015, 89, 3763-3775.	3.4	73
38	Antibody Titer Has Positive Predictive Value for Vaccine Protection against Challenge with Natural Antigenic-Drift Variants of H5N1 High-Pathogenicity Avian Influenza Viruses from Indonesia. Journal of Virology, 2015, 89, 3746-3762.	3.4	80
39	Mapping Enterovirus A71 Antigenic Determinants from Viral Evolution. Journal of Virology, 2015, 89, 11500-11506.	3.4	28
40	Dengue viruses cluster antigenically but not as discrete serotypes. Science, 2015, 349, 1338-1343.	12.6	195
41	Reply: Letter to the Editor, Cochrane Rearranged. Vaccine, 2015, 33, 13-14.	3.8	3
42	Integrating influenza antigenic dynamics with molecular evolution. ELife, 2014, 3, e01914.	6.0	299
43	Influenza Gain-of-Function Experiments: Their Role in Vaccine Virus Recommendation and Pandemic Preparedness. MBio, 2014, 5, .	4.1	26
44	Unifying Viral Genetics and Human Transportation Data to Predict the Global Transmission Dynamics of Human Influenza H3N2. PLoS Pathogens, 2014, 10, e1003932.	4.7	330
45	Circulation of Reassortant Influenza A(H7N9) Viruses in Poultry and Humans, Guangdong Province, China, 2013. Emerging Infectious Diseases, 2014, 20, 2034-2040.	4.3	41
46	Antigenic Variation of Clade 2.1 H5N1 Virus Is Determined by a Few Amino Acid Substitutions Immediately Adjacent to the Receptor Binding Site. MBio, 2014, 5, e01070-14.	4.1	57
47	Antigenic variation of foot-and-mouth disease virus serotype A. Journal of General Virology, 2014, 95, 384-392.	2.9	42
48	Excessive production and extreme editing of human metapneumovirus defective interfering RNA is associated with type I IFN induction. Journal of General Virology, 2014, 95, 1625-1633.	2.9	40
49	Genomewide Analysis of Reassortment and Evolution of Human Influenza A(H3N2) Viruses Circulating between 1968 and 2011. Journal of Virology, 2014, 88, 2844-2857.	3.4	137
50	Antibody landscapes after influenza virus infection or vaccination. Science, 2014, 346, 996-1000.	12.6	379
51	Correction for Koel et al., Antigenic Variation of Clade 2.1 H5N1 Virus Is Determined by a Few Amino Acid Substitutions Immediately Adjacent to the Receptor Binding Site. MBio, 2014, 5, .	4.1	6
52	WHO recommendations for the viruses used in the 2013–2014 Northern Hemisphere influenza vaccine: Epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from October 2012 to January 2013. Vaccine, 2014, 32, 4713-4725.	3.8	102
53	Circulating Avian Influenza Viruses Closely Related to the 1918 Virus Have Pandemic Potential. Cell Host and Microbe, 2014, 15, 692-705.	11.0	71
54	A Recommended Numbering Scheme for Influenza A HA Subtypes. PLoS ONE, 2014, 9, e112302.	2.5	137

#	Article	IF	CITATIONS
55	Serological Evidence for Non-Lethal Exposures of Mongolian Wild Birds to Highly Pathogenic Avian Influenza H5N1 Virus. PLoS ONE, 2014, 9, e113569.	2.5	18
56	Limited airborne transmission of H7N9 influenza A virus between ferrets. Nature, 2013, 501, 560-563.	27.8	182
57	Cochrane re-arranged: Support for policies to vaccinate elderly people against influenza. Vaccine, 2013, 31, 6030-6033.	3.8	135
58	Substitutions Near the Receptor Binding Site Determine Major Antigenic Change During Influenza Virus Evolution. Science, 2013, 342, 976-979.	12.6	500
59	Gain-of-Function Experiments on H7N9. Science, 2013, 341, 612-613.	12.6	24
60	Gain-of-Function Experiments on H7N9. Science, 2013, 341, 612-613.	12.6	16
61	Avian Influenza Virus Surveillance in Wild Birds in Georgia: 2009–2011. PLoS ONE, 2013, 8, e58534.	2.5	42
62	WHO recommendations for the viruses to be used in the 2012 Southern Hemisphere Influenza Vaccine: Epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from February to September 2011. Vaccine, 2012, 30, 6461-6471.	3.8	60
63	A review of influenza haemagglutinin receptor binding as it relates to pandemic properties. Vaccine, 2012, 30, 4369-4376.	3.8	51
64	Genetic evolution of the neuraminidase of influenza A (H3N2) viruses from 1968 to 2009 and its correspondence to haemagglutinin evolution. Journal of General Virology, 2012, 93, 1996-2007.	2.9	57
65	Airborne Transmission of Influenza A/H5N1 Virus Between Ferrets. Science, 2012, 336, 1534-1541.	12.6	1,416
66	The Potential for Respiratory Droplet–Transmissible A/H5N1 Influenza Virus to Evolve in a Mammalian Host. Science, 2012, 336, 1541-1547.	12.6	286
67	H7 avian influenza virus vaccines protect chickens against challenge with antigenically diverse isolates. Vaccine, 2011, 29, 7424-7429.	3.8	53
68	Flavivirus-induced antibody cross-reactivity. Journal of General Virology, 2011, 92, 2821-2829.	2.9	214
69	Prevalence of Antibodies against Seasonal Influenza A and B Viruses in Children in Netherlands. Vaccine Journal, 2011, 18, 469-476.	3.1	155
70	Evolution of re-emergent virus and its impact on enterovirus 71 epidemics. Experimental Biology and Medicine, 2011, 236, 899-908.	2.4	48
71	Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 20748-20753.	7.1	188
72	Antigenic and Genetic Evolution of Equine Influenza A (H3N8) Virus from 1968 to 2007. Journal of Virology, 2011, 85, 12742-12749.	3.4	89

#	Article	IF	CITATIONS
73	Genetic and antigenic characterization of H1 influenza viruses from United States swine from 2008. Journal of General Virology, 2011, 92, 919-930.	2.9	123
74	Use of Antigenic Cartography in Vaccine Seed Strain Selection. Avian Diseases, 2010, 54, 220-223.	1.0	54
75	Virulence-Associated Substitution D222G in the Hemagglutinin of 2009 Pandemic Influenza A(H1N1) Virus Affects Receptor Binding. Journal of Virology, 2010, 84, 11802-11813.	3.4	197
76	Quantifying Antigenic Relationships among the Lyssaviruses. Journal of Virology, 2010, 84, 11841-11848.	3.4	83
77	Studies Needed to Address Public Health Challenges of the 2009 H1N1 Influenza Pandemic: Insights from Modeling. PLoS Medicine, 2010, 7, e1000275.	8.4	75
78	Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: Basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009–2010 Northern Hemisphere season. Vaccine, 2010, 28, 1156-1167.	3.8	145
79	Quantifying the Impact of Immune Escape on Transmission Dynamics of Influenza. Science, 2009, 326, 726-728.	12.6	96
80	Reemergence of Enterovirus 71 in 2008 in Taiwan: Dynamics of Genetic and Antigenic Evolution from 1998 to 2008. Journal of Clinical Microbiology, 2009, 47, 3653-3662.	3.9	168
81	Evaluation of serological trials submitted for annual re-licensure of influenza vaccines to regulatory authorities between 1992 and 2002. Vaccine, 2009, 28, 392-397.	3.8	16
82	Antigenic and Genetic Characteristics of Swine-Origin 2009 A(H1N1) Influenza Viruses Circulating in Humans. Science, 2009, 325, 197-201.	12.6	2,127
83	Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses. Vaccine, 2008, 26, D31-D34.	3.8	208
84	The Global Circulation of Seasonal Influenza A (H3N2) Viruses. Science, 2008, 320, 340-346.	12.6	628
85	Antigenic and Genetic Evolution of Swine Influenza A (H3N2) Viruses in Europe. Journal of Virology, 2007, 81, 4315-4322.	3.4	169
86	An amino acid substitution in the influenza A virus hemagglutinin associated with escape from recognition by human virus-specific CD4+ T-cells. Virus Research, 2007, 126, 282-287.	2.2	15
87	Vaccination against highly pathogenic avian influenza H5N1 virus in zoos using an adjuvanted inactivated H5N2 vaccine. Vaccine, 2007, 25, 3800-3808.	3.8	36
88	Predictability and Preparedness in Influenza Control. Science, 2006, 312, 392-394.	12.6	67
89	Full restoration of viral fitness by multiple compensatory co-mutations in the nucleoprotein of influenza A virus cytotoxic T-lymphocyte escape mutants. Journal of General Virology, 2005, 86, 1801-1805.	2.9	52
90	Characterization of a Novel Influenza A Virus Hemagglutinin Subtype (H16) Obtained from Black-Headed Gulls. Journal of Virology, 2005, 79, 2814-2822.	3.4	1,274

DEREK J SMITH

#	Article	IF	CITATIONS
91	Recognition of Homo- and Heterosubtypic Variants of Influenza A Viruses by Human CD8+ T Lymphocytes. Journal of Immunology, 2004, 172, 2453-2460.	0.8	121
92	Annual Revaccination Against Influenza and Mortality Risk in Community-Dwelling Elderly Persons. JAMA - Journal of the American Medical Association, 2004, 292, 2089.	7.4	140
93	Mapping the Antigenic and Genetic Evolution of Influenza Virus. Science, 2004, 305, 371-376.	12.6	1,527
94	Recognition of influenza virus epitope variants by human CTL. International Congress Series, 2004, 1263, 145-148.	0.2	1
95	Mutations, drift, and the influenza archipelago. Discovery Medicine, 2004, 4, 371-7.	0.5	3
96	Applications of bioinformatics and computational biology to influenza surveillance and vaccine strain selection. Vaccine, 2003, 21, 1758-1761.	3.8	26
97	Modeling the effects of updating the influenza vaccine on the efficacy of repeated vaccination. International Congress Series, 2001, 1219, 655-660.	0.2	5
98	Variable efficacy of repeated annual influenza vaccination. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 14001-14006.	7.1	347
99	Immunological Memory is Associative*. , 1999, , 105-114.		29
100	Modeling the Effects of Prior Infection on Vaccine Efficacy. , 1999, , 144-153.		4
101	Using Lazy Evaluation to Simulate Realistic-size Repertoires in Models of the Immune System. Bulletin of Mathematical Biology, 1998, 60, 647-658.	1.9	18
102	Deriving Shape Space Parameters from Immunological Data. Journal of Theoretical Biology, 1997, 189, 141-150.	1.7	66
103	Modeling the effects of prior infection on vaccine efficacy. , 0, , .		5
104	Antigenic Cartography of Human and Swine Influenza A (H3N2) Viruses. Novartis Foundation Symposium, 0, , 32-44.	1.1	1